ARKG - ARK Genomic Revolution ETF

NYSEArca - NYSEArca Delayed Price. Currency in USD
31.85
-0.80 (-2.45%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close32.65
Open32.79
Bid0.00 x 900
Ask32.54 x 800
Day's Range31.85 - 32.79
52 Week Range21.98 - 34.78
Volume190,713
Avg. Volume159,145
Net Assets387.69M
NAV32.89
PE Ratio (TTM)N/A
Yield0.00%
YTD Return36.81%
Beta (3Y Monthly)1.99
Expense Ratio (net)0.75%
Inception Date2014-10-30
Trade prices are not sourced from all markets
  • Why These Innovative Biotech ETFs Soaring
    Zacks13 hours ago

    Why These Innovative Biotech ETFs Soaring

    Strong M&A activity has sent shares of many small, innovative biotech companies surging

  • ETF Database4 days ago

    4 ETFs to Help Investors Access Innovative Disruptors

    New disruptive technologies are changing the way we interact with the world, providing growth opportunities for exchange traded fund investors whom are looking to diversify into these quickly developing segments.

  • ETF Trends4 days ago

    4 ARK ETFs to Help Investors Access Innovative Disruptors

    New disruptive technologies are changing the way we interact with the world, providing growth opportunities for exchange traded fund investors whom are looking to diversify into these quickly developing ...

  • S&P 500 Hits New High: 10 Top-Performing ETFs YTD
    Zacks4 days ago

    S&P 500 Hits New High: 10 Top-Performing ETFs YTD

    Braving global growth concerns, the bulls are back with the S&P 500 surging to its first record close since April.

  • Pfizer-Array Biopharma Deal Bump Up Biotech ETFs
    Zacks7 days ago

    Pfizer-Array Biopharma Deal Bump Up Biotech ETFs

    Pfizer struck a deal to acquire the cancer drugmaker Array Biopharma for $11 billion in an all-cash consideration.

  • ETF Winners & Losers As China Retaliates
    Zackslast month

    ETF Winners & Losers As China Retaliates

    The renewed trade spat has led to just a few winners but a number of losers from various corners of the investing space.

  • ETF Trends2 months ago

    3 Biotech Sector ETFs Bucked the Risk-Off Trend

    While the rest of the markets retreated on a round of risk-off selling in response to President Donald Trump’s threats to raise Chinese tariffs, biotechnology stocks and sector-related exchange traded ...

  • Forget Earnings Recession: Tap Revenue Growth With These ETFs
    Zacks2 months ago

    Forget Earnings Recession: Tap Revenue Growth With These ETFs

    First-quarter earnings growth is likely to be negative this year, but revenues will grow. So, play revenue growth with these sector ETFs.

  • Biotechnology Market on a Tear: 5 ETFs in Spotlight
    Zacks2 months ago

    Biotechnology Market on a Tear: 5 ETFs in Spotlight

    Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to accelerate the biotech market. Accordingly, ETFs with exposure to the sector continue to shine.

  • Global X Launches GNOM ETF to Tap Booming Genomics Space
    Zacks2 months ago

    Global X Launches GNOM ETF to Tap Booming Genomics Space

    Having exposure to trending areas like Robotics & AI, e-commerce and IoT, Global X is set to gain from the booming genomics market with the GNOM ETF.

  • Best Performing ETFs of the First Quarter
    Zacks3 months ago

    Best Performing ETFs of the First Quarter

    Major indexes posted their best quarterly performance since the financial crisis; here are some ETFs that soared during the quarter

  • ETF Trends3 months ago

    5 ETFs That Were on Fire in the First Quarter

    With the books closing on the first quarter of 2019, it’s been a strong start for U.S. equities–the Dow Jones Industrial is up 12.56 percent through Monday’s close, the S&P 500 is up 14.37 percent and ...

  • These 3 ETFs Have Crushed It in 2019
    Motley Fool3 months ago

    These 3 ETFs Have Crushed It in 2019

    Find out how one of these exchange-traded funds took investors higher than any other.

  • ETFs That Topped & Flopped in Q1
    Zacks3 months ago

    ETFs That Topped & Flopped in Q1

    We have highlighted both the best and worst performing ETFs of Q1 from different zones or industries.

  • 4 Market-Beating Sector ETFs of the First Quarter
    Zacks3 months ago

    4 Market-Beating Sector ETFs of the First Quarter

    We have highlighted four sector ETFs that have been the quarter's star performers and could also be winners next quarter if the current trends continue.

  • 4 Best-Performing Sector ETFs of March
    Zacks3 months ago

    4 Best-Performing Sector ETFs of March

    A few sector ETFs have easily outperformed the market and are trading in the green this month.

  • Best & Worst ETFs of Last Week
    Zacks3 months ago

    Best & Worst ETFs of Last Week

    Inside the top-and-under-performing ETFs of last week.

  • ETF Trends4 months ago

    A Specialty Biotech ETF Strengthens on Optimism Over CRISPR Advancements

    A targeted biotechnology ETF strategy jumped Friday after Editas Medicine (NasdaqGS: EDIT) announced fourth quarter results, revealing its latest progress toward the commercialization of its EDIT-101 drug ...

  • ETF Database4 months ago

    Biotech ETF Strengthens on Optimism Over CRISPR Advancements

    A targeted biotechnology ETF strategy jumped Friday after Editas Medicine (EDIT) announced fourth quarter results, revealing its latest progress toward the commercialization of its EDIT-101 drug candidate and its expansion into other novel CRISPR developments.

  • 4 Best-Performing Sector ETFs of February
    Zacks4 months ago

    4 Best-Performing Sector ETFs of February

    We have highlighted four sectors ETFs that have gained double-digits in February and could be better plays in the months ahead.

  • InvestorPlace4 months ago

    7 of the Best Biotech ETFs

    After slumping last year, biotechnology stocks and the related exchange traded funds (ETFs) are on the mend in 2019. Last year, the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB), the largest biotech ETF by assets, slipped 9.5%.With almost two months of 2019 in the books, IBB has recouped all of those losses and then some as the benchmark biotechnology ETF is higher by nearly 17% this year. Amid ongoing industry consolidation, attractive valuations for a group that is often richly valued and a strong broad market, catalysts are in place for more upside for biotechnology ETFs.Jefferies analyst Michael Yee "writes that third-party data shows that the fourth quarter saw not only the biggest actively managed fund outflows in the biopharma space in 15 years, but outflows that were double the biotech bear market of 2016," according to Barron's.InvestorPlace - Stock Market News, Stock Advice & Trading TipsStill, flows data suggest investors need some convincing about returning to biotechnology ETFs. Year-to-date, IBB has lost $382.28 million in assets. * 7 IPOs to Get Excited for in 2019 Those outflows should convince investors to shy away from biotechnology ETFs. Here are some fine ideas among biotech ETFs to consider right here, right now. ALPS Medical Breakthroughs ETF (SBIO)Expense Ratio: 0.5% per year, or $50 on a $10,000 investment.For investors willing to take some more risk due to the fund's mid- and small-cap composition, the ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) is one of the best alternatives to traditional biotech ETFs. SBIO member firms have market values ranging from $200 million to $5 billion.That puts the fund at the epicenter of some prominent biotech themes. SBIO is not designed to be a takeover fund, but with market caps that do not exceed $5 billion when the fund rebalances, SBIO components have frequently been mentioned as takeover targets or outright acquired in the fund's four-plus years on the market.Second, smaller biotech companies are often more sensitive to positive trial news than large-cap counterparts, which is relevant to SBIO because the fund only holds companies with drugs or treatments in Phase II of Phase III clinical trials. Invesco Dynamic Biotechnology & Genome ETF (PBE)Expense Ratio: 0.59%The Invesco Dynamic Biotechnology & Genome ETF (NYSEARCA:PBE) is a biotech ETF to consider for investors looking for a unique weighting methodology. This $281.4 million fund follows the Dynamic Biotech & Genome Intellidex Index."The Intellidex Index is designed to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including price momentum, earnings momentum, quality, management action, and value," according to Invesco. * 10 Blue-Chip Stocks to Lead the Market Over the past three years, this biotech ETF has handily outperformed IBB, and much of that out-performance is attributable to the size factor. Currently, over 70% of PBE's 29 holdings are classified as mid- or small-cap stocks. Invesco S&P SmallCap Health Care ETF (PSCH)Expense Ratio: 0.29%Small-cap ETFs can offer big returns, and for investors willing to get tactical, some sector funds in this space can really pack a punch. That group certainly includes the Invesco S&P SmallCap Health Care ETF(NASDAQ:PSCH).As its name implies, PSCH is a broader healthcare fund, not a dedicated biotech ETF, but the combination of healthcare and small-cap stocks often means significant biotechnology exposure. PSCH obliges with a 19.46% to biotechnology stocks. Not surprisingly, PSCH is predominantly a small-cap growth fund as about 72% of its 69 holdings are classified as small-cap growth stocks.Since inception nearly nine years ago, PSCH has beaten the S&P SmallCap 600 Index by more than 700 basis points. Global X Longevity Thematic ETF (LNGR)Expense Ratio: 0.5%The Global X Longevity Thematic ETF (NASDAQ:LNGR) is a thematic fund focusing on the issue of rapidly aging populations in some of the world's largest economies. Via that focus, LNGR has some credibility as a biotechnology ETF as biotech stocks represent around a third of the fund's weight.While LNGR is a highly focused fund and still small in terms of assets, there are compelling long-term trends backing its investment thesis. * 7 Cheap Stocks That Make the Grade "As more people age, there will simply be greater demand for treatments, both old and new, to prevent, mitigate and ideally cure such diseases," according to Global X research. "Innovations in technology and biotech research, including the use of genomic data and bioinformatics for personalized care, can offer further solutions in this space." ARK Genomic Revolution ETF (ARKG)Expense Ratio: 0.75%The actively managed ARK Genomic Revolution ETF (NYSEARCA:ARKG) is not a biotechnology ETF, but it focuses on some of the most compelling healthcare opportunities, including bioinformatics, CRISPR, molecular diagnostics, stem cell therapies and more."Companies within ARKG are focused on and are expected to substantially benefit from extending and enhancing the quality of human and other life by incorporating technological and scientific developments and advancements in genomics into their business," according to ARK Investment Management.The $254 million ARKG usually holds 30 to 50 stocks and the current weighted average market value of its holdings is $30 billion. While ARKG is pricier than traditional healthcare and biotech ETFs, the fund is worth the higher fee. Over the past three years, ARKG is up 91.3%, nearly doubling the returns of the S&P 500 Health Care Index. First Trust NYSE Arca Biotechnology Index Fund (FBT)ExpenseRatio: 0.56%The First Trust NYSE Arca Biotechnology Index Fund (NYSEARCA:FBT) is one of the largest and more traditional biotech ETFs. Home to 30 stocks, FBT follows the NYSE Arca Biotechnology Index.Although FBT appears to be a basic big pharma ETF, none of its holdings exceed weights of 3.94% and the size factor is at play with this fund as highlighted by a median market capitalization of $8.18 billion for its holdings. * 9 High-Growth Stocks to Buy Now for Monster Returns Tilting toward small biotech stocks has helped FBT top the largest cap-weighted biotech ETF by a margin of better than 2-to-1 over the past 36 months. During that span, FBT has only been slightly more volatile than its cap-weighted rival. Principal Healthcare Innovators Index ETF (BTEC)Expense Ratio: 0.42%The Principal Healthcare Innovators Index ETF (NASDAQ:BTEC), which debuted in August 2016, is another example of a thematic approach to healthcare investing. BTEC tracks the Nasdaq U.S. Healthcare Innovators Index, which is comprised of early stage, small-cap names."These are primarily biotechnology and life science, which have the potential to create cures for cancer, develop new medical technologies, or spearhead other medical advances," according to ETF Trends.BTEC is not a pure biotech ETF, but at the end of last year, 60.57% of the fund's weight was allocated to biotech stocks. When BTEC rebalances none of its holdings exceed weights of 3% and at the end of 2018, the fund's top 10 holdings represented just over 29% of its weight. Those are two traits that help diminish concentration risk.As of this writing, Todd Shriber did not own any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Consumer Stocks to Buy and Hold for Years * 4 China Stocks Soaring on Trade Hopes * 3 Esports Stocks to Benefit From the Boom Compare Brokers The post 7 of the Best Biotech ETFs appeared first on InvestorPlace.

  • Biotech ETFs Jump on Roche-Spark Deal
    Zacks4 months ago

    Biotech ETFs Jump on Roche-Spark Deal

    The news of Roche-Spark Deal has triggered speculations of merger wave in the gene therapy industry and pushed the biotech ETFs higher.

  • ETF Trends5 months ago

    New ETF Launches to Take Advantage of Growing Fintech Industry

    ARK Investment Management LLC (ARK), a New York-based adviser focused solely on disruptive innovation, today launched the ARK Fintech Innovation ETF (ARKF)–an ETF that capitalizes on the burgeoning fintech ...

  • Best & Worst Performing ETFs to Start 2019
    Zacks5 months ago

    Best & Worst Performing ETFs to Start 2019

    We have highlighted some ETFs that are off to a good start in 2019 and some that have had a rough start.